DRG Epidemiology's coverage of AR comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the prevalence of allergic rhinitis for each country as well as annualized case counts projected to the national population.

Patient populations are forecast over a period of 20 years for the countries covered in this report.

DRG Epidemiology's allergic rhinitis forecast will answer the following questions:

  • Of all people with allergic rhinitis, how many in each country across the major mature pharmaceutical markets have been formally diagnosed?
  • Of all people diagnosed with allergic rhinitis, how many in each country across the major mature pharmaceutical markets are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of allergic rhinitis over the forecast period?

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In addition to the total number of cases for each forecast year, DRG Epidemiology provides at least ten years of forecast data for the following allergic rhinitis subpopulations:

  • Prevalent cases by symptom duration.
  • Prevalent cases by symptom severity.

Table of contents

  • Allergic Rhinitis - Epidemiology - Mature Markets Data
    • Introduction
      • Key Findings
      • Key Updates
      • Prevalence of Allergic Rhinitis per 1,000 People of All Ages in 2018 and 2038
      • Relative Sizes of the Contributing Factors to the Trend in Prevalent Cases of Allergic Rhinitis Over the Next 20 Years
      • Analysis of the Prevalent Cases of Allergic Rhinitis in 2018 by Diagnosed and Drug-Treated Status
      • Analysis of the Prevalent Cases of Allergic Rhinitis in 2018 by Symptom Duration
      • Analysis of the Prevalent Cases of Allergic Rhinitis in 2018 by Symptom Severity
    • Epidemiology Data
    • Methods
      • Self-Reported Total Prevalent Cases
      • Self-Reported Total Prevalence by Symptom Duration
      • Self-Reported Total Prevalence by Symptom Severity
      • Diagnosed Prevalent Cases
      • Drug-Treated Prevalent Cases
    • Reference Materials
      • Literature Review
        • Studies Included in the Analysis of Allergic Rhinitis
        • Studies Excluded from the Analysis of Allergic Rhinitis
      • Risk/Protective Factors
        • Risk/Protective Factors for Allergic Rhinitis
      • Bibliography

Author(s): Ruchika Sharma, MPH; Alison Isherwood, MSc, MRes, PhD

Ruchika Sharma joined Decision Resources Group as Associate Epidemiologist in May 2016. She performs fully documented systematic reviews of both published and grey literature on the epidemiology of assigned diseases and their risk factors to estimate incidence/prevalence over a 10-30 year period. She produces analyses for pharmaceutical drug developers on the descriptive epidemiology of major drug indications in mature and developing markets.

She holds a Master of Public Health degree from School of Public Health, Post-Graduate Institute of Medical Education and Research, and a Bachelor of Dental Surgery from MN DAV Dental College & Hospital.She has previously worked as a dental surgeon and as a Fellow at the National Health Systems Resource Centre, where she supported the preparation of National Health Accounts - Guidelines for India 2016.

Alison Isherwood, B.Sc., M.Res., M.Sc., Ph.D. joined Decision Resources Group in 2008, as an Epidemiologist. Alison holds a B.Sc. in Medical Microbiology, Masters by Research in the Life Sciences and a M.Sc. in Epidemiology all from the University of Edinburgh. Prior to joining Decision Resources Inc., she was working on her Ph.D. in Molecular Virology, specializing on the severe acute respiratory syndrome (SARS) coronavirus, at the University of Reading. In her role at Decision Resources Group, Alison is currently an Epidemiology team lead as well as project managing custom epidemiology work in multiple therapy areas. Alison’s area of specialization at DRG is cancer, particularly breast cancer.